CareDx (CDNA) EBT Margin (2013 - 2026)

CareDx (CDNA) posted EBT Margin of 86.79% for Q2 2026, up 3578.51% sequentially from 2.36% in Q1 2026, and up 9681.0% YoY from 0.89% in Q2 2025.

CareDx (CDNA) EBT Margin (2013 - 2026) Analysis & Trends

CareDx has reported EBT Margin for 14 years, with the latest figure at 86.79% in Q2 2026.

Quarterly EBT Margin rose 9681.0% year-over-year to 86.79% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 25.15% (up 800.0% YoY) and the FY2025 annual result came in at 5.55%, down 2139.0% from the prior year.
EBT Margin grew to 86.79% in Q2 2026 per CDNA's latest filing, from 2.36% in the prior quarter.
Over five years, EBT Margin peaked at 101.49% in Q4 2024 and troughed at 179.86% in Q4 2023.
A 5-year average of 14.14% and a median of 16.8% in 2024 frame the typical range for EBT Margin.
The sharpest annual moves came in 2023 and 2024: EBT Margin tumbled 15782 bps in 2023, then soared 28135 bps in 2024.
Over 5 years, EBT Margin stood at 22.04% in 2022, then tumbled by 716 bps to 179.86% in 2023, then jumped by 156 bps to 101.49% in 2024, then sank by 103 bps to 3.47% in 2025, then soared by 2600 bps to 86.79% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 86.79%, 2.36%, and 3.47% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn	16.04%
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn	17.21%
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn	34.29%
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn	22.23%
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn	6.89%
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn	-12.17%
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn	22.43%
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn	28.17%
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn	13.54%
10	CareDx	2.35 Bn	1.98 Bn	116.03 Mn	86.79%

Download Data